Objectives: High levels of low-density lipoprotein cholesterol (LDL-C) are a risk factor for cardiovascular disease. We validated the efficacy of the Martin method is useful in the estimation of LDL-C levels was validated in Japanese populations and derived a modified Martin method for easy laboratory information system applications.
Methods: We created 3 subject groups, including 2664 health check-up participants registered with the Resource Center for Health Science, 29806 clinical patients (A) in the Gifu University Hospital, and 113716 clinical patients (B) in the Fujita Health University Hospital. Each method to estimate serum LDL-C levels (Friedewald formula, Martin method, and modified Martin method) was validated by correlation analysis with serum LDL-C levels measured using a direct method
Results: The correlation coefficients with the direct method in terms of the Friedewald formula, Martin method, and modified Martin method were 0.963, 0.972, and 0.970 in the health check-up participants; 0.946, 0.962, and 0.961 in clinical patients A,; and 0.961, 0.979, and 0.978 in clinical patients B; respectively. Concordance ratios with using the direct method in the Friedewald formula, Martin method, and modified Martin method were 82.8%, 85.5%, and 85.3% in the health check-up participants; 76.4%, 80.5%, and 80.2% in clinical patients A; and 76.1%, 82.6%, and 82.6% in clinical patients B; respectively.
Conclusion: Our results show that the Martin and modified Martin methods display good performance in terms of the estimation of LDL-C levels among TG levels of a wide range, and they may thus be useful for estimating LDL-C levels.
Background: Progranulin (GP88) is an 88-kDa glycoprotein growth factor with important biological effects in tumorigenesis and tumor survival. We investigated the usefulness of measuring serum GP88 (sGP88) levels as a predictive biomarker for hepatocellular carcinoma (HCC) in patients with viral hepatitis C after treatment with direct-acting antiviral (DAA) agents. Methods: We measured the sGP88 levels by using a sandwich enzyme-linked immunoassay from 67 healthy control subjects and 29 patients (20 patients who did not develop HCC and 9 patients who developed HCC after treatment) with viral hepatitis C after treatment with asunaprevir and daclatasvir. Results: The sGP88 levels of patients with chronic hepatitis C prior to antiviral treatment were significantly higher than those of healthy control subjects. After antiviral treatment, the sGP88 levels of patients who eventually developed HCC were significantly higher than those who did not develop HCC. The changes in the sGP88 levels before and after treatment in patients who developed HCC were significantly lower than those in patients who did not develop HCC. The cumulative incidence of HCC was significantly higher in either patients with high sGP88 levels after treatment or those with small changes of sGP88 levels pre- and post-treatment. Conclusions: Sustained high levels of sGP88 in patients treated with DAA agents are correlated with the risk of developing HCC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.